JNJ 73763989
Alternative Names: ARO-HBV; GSK-5637608; JNJ-3989; JNJ-73763989Latest Information Update: 03 Sep 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Developer Arrowhead Pharmaceuticals; Janssen Research & Development; Janssen Sciences Ireland UC; Johnson & Johnson Innovative Medicine
- Class Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 05 Aug 2024 GSK plans a phase II B-UNITED trial for Hepatitis B (treatment experienced) (NCT06537414)
- 26 Jun 2024 Janssen Research & Development completes a phase-I clinical trials in Hepatitis B (Combination therapy) in United Kingdom, Taiwan, Poland, Italy, France, Spain, Belgium and Netherlands (IM) (NCT05123599)
- 05 Jun 2024 Efficacy and adverse events data from the phase II OCTOPUS-1 trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)